Podcasts

Andrew G. Lee, MD, and Drew Carey, MD, discuss findings from a retrospective study examining ischemic stroke risk in patients with non-arteritic anterior ischemic optic neuropathy and the implications for vascular risk factor management.

Ophthalmology Times® On Air

Not every question in the management of patients with GA has a clear answer—the two retina specialists work through the ones clinicians face most often in practice.

Their conversation covers a holistic, cross-specialty approach to ocular surface disease and the unmet need driving a new model of dry eye care in Ireland.

For Jay S. Duker, MD, and Ramiro Ribeiro, MD, PhD, paths that began in clinical and academic medicine became the foundation for a different kind of work—leading drug development from the inside.

Douglas D. Koch, MD, and Karolinne Maia Rocha, MD, PhD, discuss the optics behind enhanced monofocal lenses, patient selection, and how to set expectations.

Host Deborah Ristvedt, DO, welcomes Vance Thompson, MD, to discuss how prioritizing people has shaped the culture and growth of Vance Thompson Vision.

In the latest episode of The Retina TL;DR with Dr. Weng, host Christina Y. Weng, MD, MBA, FASRS, talks with Dr. Eichenbaum about the cell and gene therapy pipeline ahead, what sustains a career in retina, and why lifting others up is just what you do.

NYU Langone’s Jordan Mandell, MD, and Ariana Levin, MD, sit down with UCLA’s Anne Coleman, MD, to discuss her recent study on cardiovascular risk scores and their association with glaucoma, AMD, and other ocular diseases.

Andrew G. Lee, MD, and Drew Carey, MD, discuss recurrence of papilledema after discontinuation of GLP-1 receptor agonists and the implications for monitoring patients with idiopathic intracranial hypertension.

In the latest episode of The Retina TL;DR with Dr. Weng, host Christina Y. Weng, MD, MBA, FASRS, talks with Dr. Murdock about how the rise of "Ozempic face" has placed aesthetic injectables at the intersection of oculoplastics and retina.

Andrew G. Lee, MD, and Drew Carey, MD, discuss how eye and brain vascular events such as retinal vein occlusion and stroke can signal antiphospholipid syndrome and require further evaluation.

From role models to open doors, Christina Y. Weng, MD, MBA, FASRS, shares insights on career development, women in ophthalmology, evolving training models, and her work as protocol chair for the DRCR Retina Network’s Protocol AO study.

Andrew G. Lee, MD, and Drew Carey, MD, review how clinical and imaging findings relate to vision recovery after radiotherapy for optic nerve sheath meningioma.

For Jeffry D. Gerson, OD, FAAO, an early fascination with retinal disease—sparked during residency and shaped by mentorship and emerging OCT technology—led to a career focused on education and OD-MD collaboration.

Host Deborah Ristvedt, DO, welcomes Trattler to discuss how early inspirations, mentorship, collaboration, and a philosophy of simplifying complex concepts have shaped his ophthalmology career.

Andrew G. Lee, MD, and Drew Carey, MD, discuss how optic disc cupping after optic neuritis reflects nerve and ganglion cell thinning, not disease type, helping distinguish it from glaucoma.

NYU Grossman’s Preeya Mehta, MD, and Jonathan S. Williams, MD, sit down with Mount Sinai’s Louis R. Pasquale, MD, to discuss long-term safety and efficacy data from a PreserFlo microshunt trial and the role of microshunts in glaucoma surgery.

Retina experts unpack MacTel type 2—spot subtle signs, understand anti-VEGF limits, and explore emerging neuroprotective treatments.

When no retina podcast was available, Jayanth Sridhar, MD, created one—and learned lessons about branding, bandwidth, and mentorship along the way.

Their conversation focuses on anatomy-driven, individualized approaches and multidisciplinary decision-making for patients with neovascular glaucoma.

Jennifer E. Thorne, MD, PhD, discusses evidence from the ADJUST trial, including relapse risk, retreatment success, and how clinicians should monitor children when considering adalimumab discontinuation.

From artificial intelligence to home monitoring, Joel Schuman, MD, of Wills Eye Hospital, explores the innovations that could change how clinicians detect and treat glaucoma in the new year.

Retina experts unpack MacTel type 2, why anti-VEGF falls short, and how new cell-based gene therapy fits real-world care.

For Jordan M. Graff, MD, FACS, early adoption is about reigniting the thrill of discovery and navigating the rewards, risks, and realities of translating innovation into practice.

Tsu Shan Chambers shares how the film "My Eyes" uses authentic storytelling to raise awareness of inherited eye disease and the importance of preventive vision care.